Gilead(US:GILD) ZACKSยท2025-07-15 23:01Company Performance - Gilead Sciences (GILD) closed at $109.06, reflecting a -2.7% change from the previous day, underperforming the S&P 500's daily loss of 0.4% [1] - Over the past month, Gilead's shares gained 1.14%, while the Medical sector lost 1.56% and the S&P 500 gained 4.97% [1] Earnings Projections - The upcoming EPS for Gilead is projected at $2, indicating a 0.50% decline compared to the same quarter last year, with anticipated revenue of $7.03 billion, a 1.07% increase from the same quarter last year [2] - For the full year, analysts expect earnings of $7.94 per share and revenue of $28.68 billion, representing changes of +71.86% and -0.24% respectively from the previous year [3] Analyst Estimates and Rankings - Recent changes in analyst estimates for Gilead are crucial as they reflect near-term business trends, with positive revisions indicating analysts' confidence in the company's performance [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks Gilead as 2 (Buy), with a consensus EPS projection moving 0.29% higher in the past 30 days [6] Valuation Metrics - Gilead Sciences is trading at a Forward P/E ratio of 14.12, which is below the industry average of 17.7, indicating a discount compared to its peers [7] - The company has a PEG ratio of 0.72, significantly lower than the industry average PEG ratio of 1.5, suggesting favorable valuation relative to expected earnings growth [8] Industry Context - The Medical - Biomedical and Genetics industry, which includes Gilead, holds a Zacks Industry Rank of 77, placing it in the top 32% of over 250 industries [9]